CN116199785A - 多特异性抗体及其制备和使用方法 - Google Patents

多特异性抗体及其制备和使用方法 Download PDF

Info

Publication number
CN116199785A
CN116199785A CN202310141321.2A CN202310141321A CN116199785A CN 116199785 A CN116199785 A CN 116199785A CN 202310141321 A CN202310141321 A CN 202310141321A CN 116199785 A CN116199785 A CN 116199785A
Authority
CN
China
Prior art keywords
antibody
domain
antigen
cells
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202310141321.2A
Other languages
English (en)
Chinese (zh)
Inventor
朱义
欧勒·奥尔森
夏冬
大卫·耶利曼
卡特里娜·贝科娃
安妮玛丽·卢梭
比尔·布雷迪
布莱尔·伦肖
布莱恩·科瓦切维奇
梁玉
高泽人
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chengdu Bailidote Biological Pharmaceutical Co ltd
Original Assignee
Chengdu Bailidote Biological Pharmaceutical Co ltd
Seattle Immunization Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chengdu Bailidote Biological Pharmaceutical Co ltd, Seattle Immunization Co filed Critical Chengdu Bailidote Biological Pharmaceutical Co ltd
Publication of CN116199785A publication Critical patent/CN116199785A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN202310141321.2A 2017-06-25 2018-06-22 多特异性抗体及其制备和使用方法 Pending CN116199785A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762524557P 2017-06-25 2017-06-25
US62/524,557 2017-06-25
PCT/US2018/039156 WO2019005639A2 (en) 2017-06-25 2018-06-22 MULTISPECIFIC ANTIBODIES AND METHODS OF PREPARATION AND USE THEREOF
CN201880039401.4A CN110831973B (zh) 2017-06-25 2018-06-22 多特异性抗体及其制备和使用方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201880039401.4A Division CN110831973B (zh) 2017-06-25 2018-06-22 多特异性抗体及其制备和使用方法

Publications (1)

Publication Number Publication Date
CN116199785A true CN116199785A (zh) 2023-06-02

Family

ID=64742644

Family Applications (4)

Application Number Title Priority Date Filing Date
CN202310141321.2A Pending CN116199785A (zh) 2017-06-25 2018-06-22 多特异性抗体及其制备和使用方法
CN201880039401.4A Active CN110831973B (zh) 2017-06-25 2018-06-22 多特异性抗体及其制备和使用方法
CN202310141062.3A Pending CN116041530A (zh) 2017-06-25 2018-06-22 多特异性抗体及其制备和使用方法
CN202310922275.XA Pending CN116948035A (zh) 2017-06-25 2018-06-22 多特异性抗体及其制备和使用方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN201880039401.4A Active CN110831973B (zh) 2017-06-25 2018-06-22 多特异性抗体及其制备和使用方法
CN202310141062.3A Pending CN116041530A (zh) 2017-06-25 2018-06-22 多特异性抗体及其制备和使用方法
CN202310922275.XA Pending CN116948035A (zh) 2017-06-25 2018-06-22 多特异性抗体及其制备和使用方法

Country Status (10)

Country Link
US (1) US11787863B2 (cg-RX-API-DMAC7.html)
EP (1) EP3645049A4 (cg-RX-API-DMAC7.html)
JP (1) JP7399852B2 (cg-RX-API-DMAC7.html)
KR (2) KR20250024104A (cg-RX-API-DMAC7.html)
CN (4) CN116199785A (cg-RX-API-DMAC7.html)
AU (2) AU2018295118B2 (cg-RX-API-DMAC7.html)
CA (1) CA3068045A1 (cg-RX-API-DMAC7.html)
IL (2) IL313468A (cg-RX-API-DMAC7.html)
SG (1) SG11201912864SA (cg-RX-API-DMAC7.html)
WO (1) WO2019005639A2 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20260008861A9 (en) * 2017-06-25 2026-01-08 Systimmune, Inc. Anti-4-1bb antibodies and methods of making and using thereof
SG11201912865VA (en) * 2017-06-25 2020-01-30 Systimmune Inc Multi-specific antibodies and methods of making and using thereof
JP7383605B2 (ja) * 2017-06-25 2023-11-20 システィミューン, インク. 抗pd-l1抗体とその作製及び使用方法
TW201904588A (zh) * 2017-06-25 2019-02-01 美商西雅圖免疫公司 引導及導航控制蛋白質之製造及使用方法
EP3773621A4 (en) * 2018-03-27 2022-03-23 Systimmune, Inc. GUIDANCE AND NAVIGATION CONTROL PROTEINS AND METHODS FOR THEIR MANUFACTURE AND USE
UY38701A (es) 2019-05-21 2020-12-31 Novartis Ag Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas
AU2020279224B2 (en) 2019-05-21 2024-12-05 Novartis Ag Trispecific binding molecules against BCMA and uses thereof
CN118580364A (zh) * 2019-11-06 2024-09-03 西雅图免疫公司 制导和导航控制蛋白及其制备和使用方法
EP3988568A1 (en) * 2020-10-21 2022-04-27 Numab Therapeutics AG Combination treatment
CN118974091A (zh) * 2022-04-11 2024-11-15 阿斯利康(瑞典)有限公司 T细胞结合蛋白
CA3262028A1 (en) * 2022-07-15 2025-06-13 Abl Bio Inc. Anti-ROR1 antibodies, bispecific antibodies containing it, and their uses
CN120813602A (zh) * 2022-12-20 2025-10-17 英克特诺治疗公司 用于治疗癌症的组合疗法
US20240294651A1 (en) 2023-01-30 2024-09-05 Kymab Limited Antibodies
CN116143934B (zh) * 2023-03-21 2023-07-25 诺赛联合(北京)生物医学科技有限公司 一种干细胞外泌体提取试剂盒及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102448985A (zh) * 2009-05-27 2012-05-09 霍夫曼-拉罗奇有限公司 三或四特异性抗体
US20160355600A1 (en) * 2014-12-22 2016-12-08 Xencor, Inc. Trispecific antibodies

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1392359T4 (da) 2001-05-11 2013-06-10 Ludwig Inst For Cancer Res Ltd Specifikke bindingsproteiner og deres anvendelser.
CA2832136C (en) * 2002-09-27 2015-11-17 Xencor Optimized fc variants and methods for their generation
WO2007002223A2 (en) * 2005-06-20 2007-01-04 Medarex, Inc. Cd19 antibodies and their uses
US8679502B2 (en) 2007-11-13 2014-03-25 Evec Inc. Monoclonal antibodies that bind to HGM-CSF and medical compositions comprising same
US9365644B2 (en) * 2008-04-23 2016-06-14 Epitomics, Inc. Anti-TNFα antibody
BRPI1014089A2 (pt) 2009-04-02 2016-04-19 Roche Glycart Ag anticorpos multiespecíficos que compreendem anticorpos de comprimento completo e fragmentos fab de cadeia simples
GB201020995D0 (en) * 2010-12-10 2011-01-26 Bioinvent Int Ab Biological materials and uses thereof
CN103906533A (zh) * 2011-11-07 2014-07-02 米迪缪尼有限公司 多特异性和多价结合蛋白及其用途
PL3489261T3 (pl) * 2012-08-24 2021-08-16 The Regents Of The University Of California Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
US9732150B2 (en) * 2013-03-14 2017-08-15 Alderbio Holdings Llc Therapeutic use of antibodies to HGF
HK1218549A1 (zh) 2013-06-26 2017-02-24 Numab Therapeutics AG 新型抗体框架
JP6693872B2 (ja) * 2013-07-25 2020-05-13 シトムクス セラピューティクス,インコーポレイティド 多重特異性抗体、多重特異性活性化可能抗体、及びそれらの使用方法
WO2015058861A1 (en) 2013-10-25 2015-04-30 Numab Ag Bispecific constructs and their use in the treatment of various diseases
CA3265373A1 (en) * 2014-02-20 2025-10-30 H. Lundbeck A/S Anti-acth antibodies and use thereof
UA117289C2 (uk) * 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
EP3253790A4 (en) * 2015-02-06 2018-07-25 University of Maryland, Baltimore Tetra-specific, octameric binding agents and antibodies against clostridium difficile toxin a and toxin b for treatment of c. difficile infection
CN104829733B (zh) * 2015-05-25 2018-06-05 广州百暨基因科技有限公司 抗原结合单元稳定的嵌合抗原受体及制备方法与应用
JP6932700B2 (ja) * 2015-09-15 2021-09-08 アムジエン・インコーポレーテツド 4価の二重特異性抗原結合タンパク質及び4価の四重特異性抗原結合タンパク質、ならびにそれらの使用
TW201904588A (zh) * 2017-06-25 2019-02-01 美商西雅圖免疫公司 引導及導航控制蛋白質之製造及使用方法
SG11201912865VA (en) 2017-06-25 2020-01-30 Systimmune Inc Multi-specific antibodies and methods of making and using thereof
EP3773621A4 (en) * 2018-03-27 2022-03-23 Systimmune, Inc. GUIDANCE AND NAVIGATION CONTROL PROTEINS AND METHODS FOR THEIR MANUFACTURE AND USE

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102448985A (zh) * 2009-05-27 2012-05-09 霍夫曼-拉罗奇有限公司 三或四特异性抗体
US20160355600A1 (en) * 2014-12-22 2016-12-08 Xencor, Inc. Trispecific antibodies

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
THOMAS KÖHNKE等: "Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab", 《JOURNAL OF HEMATOLOGY & ONCOLOGY》, vol. 8, 8 October 2015 (2015-10-08), pages 1 - 5 *
锡建中等: "广义新型抗体的研究进展", 《黑龙江畜牧兽医》, no. 23, 10 December 2014 (2014-12-10), pages 60 - 62 *

Also Published As

Publication number Publication date
AU2018295118A1 (en) 2020-02-06
IL271257B2 (en) 2024-11-01
US20220002406A1 (en) 2022-01-06
KR20200092301A (ko) 2020-08-03
CN116948035A (zh) 2023-10-27
IL313468A (en) 2024-08-01
CN116041530A (zh) 2023-05-02
EP3645049A2 (en) 2020-05-06
EP3645049A4 (en) 2021-06-30
KR20250024104A (ko) 2025-02-18
RU2020102662A (ru) 2021-07-27
WO2019005639A2 (en) 2019-01-03
AU2018295118B2 (en) 2025-04-17
KR102763369B1 (ko) 2025-02-05
WO2019005639A3 (en) 2019-02-07
JP2020530777A (ja) 2020-10-29
SG11201912864SA (en) 2020-01-30
US11787863B2 (en) 2023-10-17
IL271257B1 (en) 2024-07-01
JP7399852B2 (ja) 2023-12-18
CN110831973A (zh) 2020-02-21
CN110831973B (zh) 2023-08-15
NZ760913A (en) 2024-10-25
AU2025204860A1 (en) 2025-07-17
CA3068045A1 (en) 2019-01-03
IL271257A (en) 2020-01-30

Similar Documents

Publication Publication Date Title
JP7685095B2 (ja) 多重特異性抗体とその作製及び使用方法
CN111148761B (zh) 多特异性抗体及其制备和使用方法
JP7399852B2 (ja) 多重特異性抗体とその作製及び使用方法
JP7464764B2 (ja) 抗ror1抗体とその作製及び使用方法
US20240279333A1 (en) Multi-specific antibodies and methods of making and using thereof
HK40088417A (en) Multi-specific antibodies and methods of making and using thereof
HK40088418A (en) Multi-specific antibodies and methods of making and using thereof
HK40093821A (en) Multi-specific antibodies and methods of making and using thereof
HK40111323A (en) Multi-specific antibodies and methods of making and using thereof
HK40111322A (en) Multi-specific antibodies and methods of making and using thereof
HK40018991A (en) Multi-specific antibodies and methods of making and using thereof
HK40019010A (en) Multi-specific antibodies and methods of making and using thereof
KR20260013450A (ko) 이중 특이적 항원 결합 분자 및 이의 응용

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40088418

Country of ref document: HK

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20240630

Address after: No. 139 Baili Road, Chengdu Cross Strait Science and Technology Industry Development Park, Wenjiang District, Chengdu City, Sichuan Province, 611130

Applicant after: Chengdu bailidote Biological Pharmaceutical Co.,Ltd.

Country or region after: China

Address before: 15318 Northeast 95th Street, Redmond, Washington, USA

Applicant before: Seattle Immunization Co.

Country or region before: U.S.A.

Applicant before: Chengdu bailidote Biological Pharmaceutical Co.,Ltd.

Country or region before: China